13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001910264
Total reported value
$1.0B
$1.0B
12 檔
54.7%
At the close of Q3 2025, Sr One Capital Management, LP disclosed equity holdings valued at approximately $1.0B, spread across 12 reported holdings.
Sr One Capital Management, LP executed strategic sector rebalancing during Q3 2025, establishing 1 new positions while fully exiting 1 holdings and trimming 1 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | Stock-Other | 27.86% | -29.43% | EXIT | |
| 2 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 19.11% | +0.11% | +94.36% | |
| 3 | ZBIO | Zenas Biopharma Inc | Stock-Other | 15.77% | +1.55% | — | |
| 4 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 11.59% | -0.57% | -32.42% | |
| 5 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 7.84% | -1.58% | — | |
| 6 | DSGN | Design Therapeutics Inc | Stock-Other | 7.11% | +1.50% | — | |
| 7 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 5.83% | -0.43% | — | |
| 8 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.20% | -2.31% | EXIT | |
| 9 | ALMS | Alumis Inc | Stock-Other | 1.13% | +0.59% | — | |
| 10 | NKTX | Nkarta Inc | Stock-Other | 1.00% | +0.14% | — | |
| 11 | OCS | Oculis Holding AG | Stock-Other | 0.82% | -1.00% | — | |
| 12 | ✓ | Engene Holdings Inc | Stock-Other | 0.74% | -0.44% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CRSP | CRISPR Therapeutics AG | +9.9% | +94.36% | Add |
| 2 | ZBIO | Zenas Biopharma Inc | +5.8% | — | Unchanged |
| 3 | DSGN | Design Therapeutics Inc | +0.6% | — | Unchanged |
| 4 | ORKA | Oruka Therapeutics Inc | +0.1% | — | Unchanged |
| 5 | ✓ | Engene Holdings Inc | -0.1% | — | Unchanged |
| 6 | NKTX | Nkarta Inc | -0.6% | — | Unchanged |
| 7 | OCS | Oculis Holding AG | -0.8% | — | Unchanged |
| 8 | MLYS | Mineralys Therapeutics Inc | -1.2% | -32.42% | Trim |
| 9 | ALMS | Alumis Inc | -2% | — | Unchanged |
| 10 | SPRY | Ars Pharmaceuticals Inc | -7.1% | — | Unchanged |
| 11 | ACLXGBX | Arcellx Inc | -11.7% | — | Unchanged |
| 12 | ORIC | Oric Pharmaceuticals Inc | — | NEW | New buy |
| 13 | KALAEUR | Kala Bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Sr One Capital Management, LP reported a total U.S. public equity portfolio value of $1.0B across 12 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACLXGBX, CRSP, ZBIO) accounted for 54.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
ORIC
市值: $54.2M
Top Position Liquidated / Trimmed
KALAEUR
前期市值: $3.4M
During Q3 2025, Sr One Capital Management, LP's top holdings by market value included ACLXGBX (27.9%)、CRSP (19.1%)、ZBIO (15.8%). The largest single position, ACLXGBX, represented 27.9% of total portfolio value.
In Q3 2025, Sr One Capital Management, LP made 4 total portfolio adjustments, initiating 1 new buys, adding to 1 positions, trimming 1 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.